Health Care • Medical/Dental Instruments
$82.29 ▲ +2.36
(+2.95%)
MKT CAP: $30.16B • VOL: 8.64M
52W L $54 52W H $93
DXCM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.66B | $4.03B | $3.62B |
| YoY Revenue Growth % | +15.6% | +11.3% | — |
| Gross Profit | $2.80B | $2.44B | — |
| Gross Margin % | 60.1% | 60.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $911.8M | $600.0M | $597.7M |
| Operating Margin % | 19.6% | 14.9% | 16.5% |
| Net Income (GAAP) | $836.3M | $576.2M | $541.5M |
| EBITDA (Normalized) | $1.20B | $887.0M | $728.1M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.44B | $989.5M | $748.5M |
| Capital Expenditures (CapEx) | $363.5M | $358.8M | $163.0M |
| Free Cash Flow (FCF) | $1.08B | $630.7M | $585.5M |
| FCF Margin % | 23.1% | 15.6% | 16.2% |
| Return on Invested Capital (ROIC %) | 20.9% | 13.7% | 4.7% |
| Cash & Short-Term Equivalents | $917.7M | $606.1M | — |
| Total Debt (Short + Long Term) | $1.62B | $1.97B | $3.88B |
| Total Stockholders' Equity | $2.75B | $2.10B | $7.96B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DXCM.